Medicare Enrolled
Dr. Don Wynn, M.D.
Pulmonary Disease · Denison, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Wynn from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wynn? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wynn
Dr. Don Wynn is a pulmonary disease in Denison, TX, with 18 years in practice. Based on federal Medicare data, Dr. Wynn performed 40,514 Medicare services across 4,711 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wynn received a total of $27,019 from 46 pharmaceutical and/or device companies across 971 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wynn is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 0% volume in TX$ $27,019 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,514
Medicare services
Top 0% in TX for pulmonary disease
4,711
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,251 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Omalizumab injection (Xolair) for asthma/allergy | 27,917 | $30 | $55 |
| Allergy skin test | 1,976 | $3 | $9 |
| Office visit, established patient (30-39 min) | 1,177 | $88 | $158 |
| Chest X-ray, 2 views | 1,047 | $24 | $43 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 1,026 | $52 | $107 |
| Ceftriaxone antibiotic injection | 804 | $0 | $2 |
| Hospital follow-up visit, high complexity | 688 | $91 | $146 |
| Office visit, established patient, complex (40-54 min) | 587 | $125 | $219 |
| Hospital follow-up visit, moderate complexity | 526 | $59 | $101 |
| Dexamethasone injection (steroid) | 415 | $0 | $1 |
| Test to determine lung volumes using sensors | 408 | $39 | $85 |
| Test to examine how well the lungs exchange gases | 406 | $42 | $77 |
| Test to measure expiratory airflow and volume | 328 | $19 | $49 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 270 | $27 | $75 |
| Test for exercise-induced lung stress | 245 | $25 | $56 |
| Injection of additional new drug or substance into vein | 199 | $11 | $33 |
| Injection, levofloxacin, 250 mg | 189 | $1 | $5 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 181 | $46 | $89 |
| Drug injection, under skin or into muscle | 181 | $10 | $34 |
| Detection test by immunoassay with direct visual observation for influenza virus | 168 | $16 | $39 |
| Critical care, first 30-74 min | 152 | $161 | $532 |
| Initial hospital admission, high complexity | 144 | $123 | $260 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 137 | $4 | $12 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 108 | $87 | $485 |
| Inhalation treatment for acute airway obstruction, first hour | 107 | $43 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 100 | $15 | $51 |
| Injection, ciprofloxacin for intravenous infusion, 200 mg | 95 | $1 | $3 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 93 | $50 | $73 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 93 | $0 | $2 |
| Detection test by nucleic acid for respiratory syncytial virus, amplified probe technique | 91 | $45 | $47 |
| New patient office visit, complex (60-74 min) | 89 | $151 | $269 |
| Sleep study in sleep lab (6 years or older) | 78 | $81 | $422 |
| Electrocardiogram (EKG), 12-lead | 70 | $11 | $38 |
| Sleep study including heart rate, breathing, airflow, and effort | 68 | $32 | $113 |
| Office visit, established patient (20-29 min) | 60 | $63 | $124 |
| Ultrasound scan of chest | 56 | $43 | $102 |
| Blood draw (venipuncture) | 53 | $5 | $5 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 49 | $83 | $329 |
| Injection of drug or substance into vein | 44 | $28 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $22 | $56 |
| New patient office visit (45-59 min) | 26 | $128 | $247 |
| Aspiration of fluid from chest cavity using imaging guidance | 15 | $88 | $744 |
| Exam of lung airways using an endoscope | 12 | $62 | $346 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
76.5% medium
22.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,019
Total received (2018-2024)
Avg $3,860/year across 7 years
Top 10% in TX for pulmonary disease
46
Companies
971
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,612 (61.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,407 (38.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$111
2023$12,045
2022$3,081
2021$3,294
2020$2,139
2019$2,915
2018$3,434
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Intuitive Surgical, Inc.
$11,269
GlaxoSmithKline, LLC.
$2,680
AstraZeneca Pharmaceuticals LP
$1,957
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,721
Mylan Specialty L.P.
$1,171
Actelion Pharmaceuticals US, Inc.
$854
Genentech USA, Inc.
$811
Pulmonx Corporation
$768
Novartis Pharmaceuticals Corporation
$618
GENZYME CORPORATION
$487
Sunovion Pharmaceuticals Inc.
$468
Grifols USA, LLC
$453
Teva Pharmaceuticals USA, Inc.
$433
United Therapeutics Corporation
$395
Regeneron Healthcare Solutions, Inc.
$341
Gilead Sciences, Inc.
$274
Takeda Pharmaceuticals U.S.A., Inc.
$256
Insmed, Inc.
$210
Philips Electronics North America Corporation
$195
Bayer HealthCare Pharmaceuticals Inc.
$182
Janssen Pharmaceuticals, Inc
$175
Mallinckrodt Hospital Products Inc.
$163
Mallinckrodt Enterprises LLC
$155
Amgen Inc.
$146
Mallinckrodt LLC
$105
Shire North American Group Inc
$100
Medtronic, Inc.
$89
Baxter Healthcare
$79
Advanced Respiratory, Inc
$67
AbbVie Inc.
$53
ANI Pharmaceuticals, Inc.
$47
ABIOMED
$40
Harmony Biosciences LLC
$32
ZOLL Respicardia, Inc.
$24
Exeltis, USA Inc.
$24
JAZZ PHARMACEUTICALS INC.
$23
ALK-Abello, Inc
$20
Merck Sharp & Dohme LLC
$17
Cumberland Pharmaceuticals, Inc.
$16
Covis Pharma GmBH
$16
Inogen, Inc.
$15
ABBVIE INC.
$15
Merck Sharp & Dohme Corporation
$15
ADVANCED RESPIRATORY, INC
$14
PFIZER INC.
$14
Circassia Pharmaceuticals Inc
$14
Top 3 companies account for 58.9% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · ANORO · ANORO ELLIPTA · ASMANEX · AVYCAZ · Adempas · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHARTIS CATHETER · CINQAIR · CUVITRU · DUPIXENT · Da Vinci Surgical System · Esbriet · FASENRA · GLASSIA · Grastek · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · INPEN SMART INSULIN DELIVERY SYSTEM · ION · Impella · InogenOne · LONHALA MAGNAIR · Letairis · Life 2000 Ventilation System · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PANZYGA · PURIFIED CORTROPHIN GEL · Perforomist · ProAir Digihaler · Prolastin-C Liquid · REMODULIN · Respiratoriy Care Undiv · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TECENTRIQ · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · UTIBRON · UTIBRON NEOHALER · Utibron · Veklury · Vibativ · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · Xembify · Xolair · YUPELRI · Yupelri · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (62%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for pulmonary disease in TX.
Equivalent to $67 per 100 Medicare services performed
Geographic Context
Pulmonary Diseases within 10 mi
4
Per 100K population
2.9
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Wynn is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (low-engagement, top 10%), with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Wynn experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Wynn performed 27,917 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wynn receive payments from pharmaceutical companies?
Yes. Dr. Wynn received a total of $27,019 from 46 companies across 971 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wynn's costs compare to other pulmonary diseases in Denison?
Dr. Wynn's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wynn) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Denison
Browse pulmonary diseases in Denison ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
Intuitive Surgical, Inc. Payments to Doctors
See all physicians who received payments from Intuitive Surgical, Inc..
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology